Naevus lightening in melanoma patients under BRAF/MEK inhibitor combination therapy versus checkpoint immunotherapy: A histological and immunohistochemistry analysis

被引：2
|
作者：
Zhao, Cathy Yunjia [1 ,2 ]
Chou, Shaun [1 ,3 ]
Liu, Rose Congwei [1 ,2 ]
Fernandez-Penas, Pablo [1 ,2 ]
机构：
[1] Westmead Hosp, Dept Dermatol, Sydney, NSW, Australia
[2] Univ Sydney, Med, Sydney, NSW, Australia
[3] Westmead Hosp, Inst Clin Pathol & Med Res, Sydney, NSW, Australia
来源：
PIGMENT CELL & MELANOMA RESEARCH | 2018年 / 31卷 / 02期
关键词：
MELANOCYTIC LESIONS;
D O I：
10.1111/pcmr.12669
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [21] A comparative study of the cutaneous side effects between BRAF monotherapy and BRAF/MEK inhibitor combination therapy in patients with advanced melanoma: a single-centre experience
    Irene Russo
    Ludovica Zorzetto
    Anna Chiara Frigo
    Vanna Chiarion Sileni
    Mauro Alaibac
    European Journal of Dermatology, 2017, 27 : 482 - 486
  • [22] A comparative study of the cutaneous side effects between BRAF monotherapy and BRAF/MEK inhibitor combination therapy in patients with advanced melanoma: a single-centre experience
    Russo, Irene
    Zorzetto, Ludovica
    Frigo, Anna Chiara
    Sileni, Vanna Chiarion
    Alaibac, Mauro
    EUROPEAN JOURNAL OF DERMATOLOGY, 2017, 27 (05) : 482 - 486
  • [23] Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care
    Goldman, Chloe
    Tchack, Jeremy
    Robinson, Eric M.
    Han, Sung Won
    Moran, Una
    Polsky, David
    Berman, Russell S.
    Shapiro, Richard L.
    Ott, Patrick A.
    Osman, Iman
    Zhong, Hua
    Pavlick, Anna C.
    Wilson, Melissa Ann
    ONCOLOGY, 2017, 93 (03) : 164 - 176
  • [24] Outcomes of BRAF mutant metastatic melanoma (MM) patients (pts) after cessation of targeted therapy (TT) with BRAF or BRAF/MEK inhibitor(i).
    Jackson, Natalie
    Rodgers, Theresa
    John, Ida
    Milton, Denai R.
    Haydu, Lauren Elaine
    Amaria, Rodabe Navroze
    Diab, Adi
    McQuade, Jennifer Leigh
    Patel, Sapna Pradyuman
    Tawbi, Hussein Abdul-Hassan
    Wong, Michael K. K.
    Davies, Michael A.
    Glitza, Isabella Claudia
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [25] The efficacy and safety of the combination of anti-BRAF agent and MEK inhibitor in advanced melanoma patients with BRAF V600 mutation: A meta-analysis.
    Xie, Changqing
    Mishriky, Basem Mourad Labib
    Chae, Phillip
    Atluri, Prashanti
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [26] Efficacy and Adverse Events in Metastatic Melanoma Patients Treated with Combination BRAF Plus MEK Inhibitors Versus BRAF Inhibitors: A Systematic Review
    Greco, Austin
    Safi, Danish
    Swami, Umang
    Ginader, Tim
    Milhem, Mohammed
    Zakharia, Yousef
    CANCERS, 2019, 11 (12)
  • [27] Sequential targeted therapy and immunotherapy of a BRAF positive metastatic melanoma patient with BRAF inhibitor vemurafenib, MEK inhibitor cobimetnib and a novel PD-1 antibody Sintilimab.
    Zhang, Yu
    Li, Xiaomo
    Ma, Tonghui
    Cao, Baoshan
    CANCER RESEARCH, 2021, 81 (13)
  • [28] Combination Immune Checkpoint Inhibitor Therapy is Associated With Increased Blood Pressure in Melanoma Patients
    Turker, Isik
    Sharma, Ananya
    Huang, Shi
    Johnson, Douglas B.
    Alexander, Matthew R.
    HYPERTENSION, 2023, 80 (03) : E43 - E45
  • [29] Safety and Tolerability of BRAF Inhibitor and BRAF Inhibitor-Based Combination Therapy in Chinese Patients With Advanced Melanoma: A Real World Study
    Liu, Xing
    Li, Jing-jing
    Ding, Ya
    Li, Dan-dan
    Wen, Xi-zhi
    Weng, De-sheng
    Wang, Jiu-hong
    Jiang, Hang
    Zhang, Xiao-shi
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [30] Effectiveness of immunotherapy versus BRAF/MEK inhibitors in treatment-naive BRAF-mutant advanced melanoma: A single institution retrospective analysis.
    Ahmed, Mamoon
    Abdullah, Hafez M.
    Ali, Mohammad
    Morris, Kahlen
    Sathyanarayanan, Swaminathan Perinkulam Perinkulam
    Ali, Lina
    Gurumoorthy, Aarabhi
    Bleeker, Jonathan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345